The Royal Oak, Michigan-based startup will use the funding to support development and commercialization of its pan-disease diagnostic testing platform.
The firm said that it is working with partners to provide collection devices that can be used at home, making it easier for people to gain access to tests.
Under the exclusive agreement, Fisher Healthcare, which is part of Thermo Fisher Scientific, will distribute the test through its channel.
The financing, led by Accelerated Digital Ventures, will go toward the development of 20 tests targeted at cancers and dementias.
The firm said that the system's automation and flexibility will help centers be more productive within a testing specialty that can require extensive hands-on time.
Seventh Sense Biosystems markets a one-step, push-button device called Tap that uses a microneedle array to collect capillary blood from the arm.
The fluid in the skin can be used to detect systemic biomarkers but has previously been too inaccessible. A new paper-based method could change that.
The Swiss company's new immunohematology microarray runs on the company's MosaiQ high-throughput automated platform for blood transfusion testing.
The NEO Iris instrument uses the company's Capture solid phase technology for antibody screening and identification, and can run up to 60 tests and screens per hour.
The Canadian company said it will use the funding to support the US launch of its rapid, noninvasive test for platelet activation status.